Results 121 to 130 of about 1,652 (181)

Transcription termination counteracts DNA damage after WEE1 inhibition. [PDF]

Nucleic Acids Res
Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG.   +12 more
europepmc   +1 more source

Computational mapping of productive POI-E3 ligase conformations to guide de novo degrader design: application to WEE1 and PKMYT1 PROTACs. [PDF]

J Cheminform
Nassar H, Schmidt M, Ibrahim HS, Robaa D, Sippl W.   +4 more
europepmc   +1 more source

Solubility Modeling for Key Organic Compounds Used in Adavosertib (Anticancer API) Manufacturing. [PDF]

ACS Omega
Blair M, Chalchooghi MM, Cox RJ, Gerogiorgis DI.   +3 more
europepmc   +1 more source

Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case study. [PDF]

Nat Commun
Knight JL, Clark AJ, Wang J, Placzek A, Bos PH, Bhat S, Bell JA, Silvergleid S, Yin W, Gray F, Sun S, Akinsanya K, Abel R, Gerasyuto AI.   +13 more
europepmc   +1 more source

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. [PDF]

NPJ Breast Cancer, 2023
Teo ZL, O'Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, Kuykhoven K, Mintoff CP, Savas P, Virassamy B, Luen SJ, Byrne A, Sant S, Lindeman GJ, Darcy PK, Loi S.   +15 more
europepmc   +1 more source

Systematic analyses to explore kinase gene set-based signature in glioma, in which WEE1 contributes to tumor progression. [PDF]

Discov Oncol
Zhang D, Li X, Mao P, Guo H, Liu Z, Wang N, Bao G, Yu H, Chen W.   +8 more
europepmc   +1 more source

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition. [PDF]

Front Cell Dev Biol
Giuntini F, Whitfield JR, Massó-Vallés D, Soucek L.   +3 more
europepmc   +1 more source

Facilitating access to clinical data from a randomized controlled trial of complex adaptive design. [PDF]

BMC Res Notes
Olago V, Yorke-Edwards V, Brown LC, Sydes M, Maughan T, Fisher D.   +5 more
europepmc   +1 more source

Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. [PDF]

PLoS One
Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B.   +5 more
europepmc   +1 more source

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights. [PDF]

NPJ Breast Cancer
Aloss K, Frederick MI, Hassan S.
europepmc   +1 more source